Your browser is unsupported

We recommend using the latest version of IE11, Edge, Chrome, Firefox or Safari.

Photo of A. Simon Pickard

Related Sites:

About Heading link

A. Simon Pickard, PhD, is a Professor in the Department of Pharmacy Systems, Outcomes and Policy, and Assistant Director of the Center for Pharmacoepidemiology and Pharmacoeconomic Research at the University of Illinois – Chicago College of Pharmacy. He earned his B.Comm., B.Sc. in Pharmacy, and PhD in Pharmacy and Pharmaceutical Sciences from the University of Alberta in Edmonton, Alberta, Canada. Dr. Pickard has authored over 150 publications on evaluating the safety, effectiveness and value of health care interventions; improving drug-related outcomes through education (particularly opioids); and on the measurement and evaluation of quality of care and health outcomes. He has served on several editorial boards, including Medical Decision Making, Drugs in Context, and Quality of Life Research. He is co-developer of the LupusPRO, a lupus specific quality of life measure. He has extensively contributed to the EuroQol Group, developers of the EQ-5D, one of the most widely used measures of health in clinical trials throughout the world, and is part of the international consortia to develop a new measure of health and well-being (EQ-HWB).

Research Interests:
Dr. Pickard’s research interests involve evaluating the safety, effectiveness and value of health care interventions; improving drug-related outcomes through education (particularly opioids); and on the measurement and evaluation of quality of care and health outcomes. H

Teaching Statement:
Dr. Pickard is an educator in the UIC professional program (PharmD) and graduate program (PhD/MS). In the PharmD program, he initiated an elective course starting Fall 2022 that provides an overview of health economic and outcomes research (HEOR). He serves as preceptor for P4 PharmD students in advanced clerkships rotations offered each year focusing on research activities related to pharmacy systems, outcomes and policy. In the PhD program for PSOP, he teaches a course on measurement and evaluation of patient-reported outcomes (PSOP 555) and an introduction to comparative effectiveness research (PSOP 516). He serves as main advisor for PhD/MS students, and as a committee member on department qualifiers, preliminary exams and dissertation defenses. He has served as a director for numerous (post-doc) fellowships in partnership with industry since 2007, including TAP, Takeda, NovoNordisk, and Pfizer.

Teaching and Supervision Heading link

Ph.D. Thesis Research (PSOP 599), 1/9/2023 – 4/28/2023
Independent Study (PSOP 596), 1/9/2023 – 4/28/2023
Patient Reported Outcomes (PSOP 555), 1/9/2023 – 4/28/2023
Independent Study (PSOP 596), 8/22/2022 – 12/2/2022
Hlth Econ & Outcomes Research (PSOP 489), 8/22/2022 – 12/2/2022
Ph.D. Thesis Research (PSOP 599), 8/22/2022 – 12/2/2022
Independent Study (PSOP 596), 1/10/2022 – 4/29/2022
Comp Effectiveness Research (PSOP 516), 1/10/2022 – 4/29/2022
Ph.D. Thesis Research (PSOP 599), 1/10/2022 – 4/29/2022

Selected Grants

Pfizer 2022 to 2025 Fellowship - Pickard, Pfizer Inc., 7/1/2022 - 6/30/2025, Obligated Amount: $482934; Anticipated Amount: $482934

Self-perceived burden, caregiver burden and EQ measures �assessing measurement overlap, EuroQol Group., 5/1/2022 - 5/1/2024, Obligated Amount: $137909; Anticipated Amount: $137909

UIC Prescription Monitoring Academic Detailing - contract 49I1127M40, Illinois Department of Human Services., 12/30/2020 - 8/31/2023, Obligated Amount: $510000; Anticipated Amount: $510000

OD2A Year 2 and 3 Evaluation IGA, Illinois Department of Public Health., 9/1/2020 - 8/31/2022, Obligated Amount: $600000; Anticipated Amount: $600000

PhD dissertation funding request for a novel valuation method, Euroqol Group Business Mgmt., 8/16/2020 - 8/15/2022, Obligated Amount: $50163; Anticipated Amount: $50163

Pilot Project for Academic Detailing, Illinois Department of Public Health., 7/1/2020 - 6/30/2021, Obligated Amount: $110000; Anticipated Amount: $110000

2020 - 2021 Institute for Clinical and Economic Review Consulting Agreement, Institute for Clinical and Economic Review., 1/1/2020 - 12/31/2021, Obligated Amount: $425000; Anticipated Amount: $425000

Impacting the Prescribing of Opioids through Academic Detailing, US Centers for Disease Control and Prevention., 9/30/2019 - 9/29/2023, Obligated Amount: $2297565; Anticipated Amount: $2297565

Impacting the Prescribing of Opioids through Academic Detailing, National Center for Injury Prevention and Control., 9/30/2019 - 9/29/2022, Obligated Amount: $2297565; No Anticipated Amount Set

Selected Publications

Hanson, KA, Smart, MH, Mandava, MR, Carkovic, E, Aslamy, M, Lee, TA, Pickard, AS. (2023). Pharmacists and Naloxone: Barriers to Dispensing and Effectiveness of an Educational Outreach Program. Journal of the American Pharmacists Association, 63, (2), 608-613.e3. doi:10.1016/j.japh.2022.12.018.

Brazier, J, Peasgood, T, Mukuria, C, Luo, N, Mulhern, B, Pickard, AS, Augustovski, F, Greiner, W, Engel, L. (2023). Author Reply. Value in Health, 26, (3), 437-440. doi:10.1016/j.jval.2022.10.010.

Nazari, JL, Pickard, AS, Gu, NY. (2022). Findings from a Roundtable Discussion with US Stakeholders on Valuation of the EQ-5D-Y-3L. PharmacoEconomics, 40, 139-146. doi:10.1007/s40273-022-01222-x.

Kuharic, M, Joshi, M, Zecic, F, Pickard, AS. (2022). PCR198 Contemporary Trends in the Use of Generic Patient-Reported Outcome Measures in Pediatric Clinical Trials: An Analysis of Clinicaltrials.Gov. Value in Health, 25, (12), s428. doi:10.1016/j.jval.2022.09.2131.

Jiang, R, Rand, K, Kuharic, M, Pickard, AS. (2022). EQ-5D-5L measurement properties are superior to EQ-5D-3L across the continuum of health using US value sets. Health and Quality of Life Outcomes, 20, (1). doi:10.1186/s12955-022-02031-8.

McTaggart-Cowan, H, King, MT, Norman, R, Costa, DSJ, Pickard, AS, Viney, R, Peacock, SJ, Chan, K, Hoch, J, Leighl, N, Mittmann, N, Regier, D. (2022). The FACT-8D, a new cancer-specific utility algorithm based on the Functional Assessment of Cancer Therapies-General (FACT-G): a Canadian valuation study. Health and Quality of Life Outcomes, 20, (1). doi:10.1186/s12955-022-02002-z.

LaBedz, SL, Prieto-Centurion, V, Mutso, A, Basu, S, Bracken, NE, Calhoun, EA, DiDomenico, RJ, Joo, M, Pickard, AS, Pittendrigh, B, Williams, MV, Illendula, S, Krishnan, JA. (2022). Pragmatic Clinical Trial to Improve Patient Experience Among Adults During Transitions from Hospital to Home: the PArTNER study. Journal of General Internal Medicine, 37, (16), 4103-4111. doi:10.1007/s11606-022-07461-0.

Kuharic, M, Monteiro, A, Pickard, AS. (2022). PCR255 The EQ Health and Wellbeing (EQ-HWB) and the Eq Health and Wellbeing Short (EQ-HWB-S) as an Outcome Measure in Mental Health and Well-Being: A Comparison to the EQ-5D-5L, EQ-5D-3L and the Short Warwick-Edinburgh Mental Well-Being Scale. Value in Health, 25, (12), s439. doi:10.1016/j.jval.2022.09.2188.

Kuharic, M, Shah, K, Hanson, K, Nazari, J, Kulbokas, V, Nguyen, A, Hensle, T, Pickard, AS. (2022). PCR71 Off Episode Quality of Life Impact Scale (OFFELIA): Overview of the Development of a Quality of Life and Functional Impact Measure of Off Episodes in Parkinson’s Disease. Value in Health, 25, (12), s403-s404. doi:10.1016/j.jval.2022.09.2006.


Ph.D., University of Alberta, Canada, 2002
B.Sc, University of Alberta, Canada, 1996
B. Comm, University of Alberta, Canada, 1991